New cell therapy offers hope for Hard-to-Treat lymphoma patients
NCT ID NCT07345741
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new treatment called AcNK-Sup003 for people with a type of blood cancer (B-cell non-Hodgkin lymphoma) that has come back or not responded to other treatments. The goal is to see if it is safe and to find the best dose. About 28 adults will take part, and researchers will track their survival for up to 24 months.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology
Wuhan, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immune cells plus a checkpoint drug outsmart lymphoma?
- Can an immune booster outsmart brain lymphoma?
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Can donor immune cells be engineered to fight blood cancer?
- Can a simple blood test spot lymphoma earlier?
- What happens years after CAR-T therapy? a study aims to find out